OPPM
KITE

Opus Point Partners Management’s Kite Pharma, Inc. KITE Stock Holding History

Opus Point Partners Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,915
Closed -$613K – 70
2017
Q2 		$613K Sell
5,915
-16
-0.3% -$1.31K 0.56% 42
2017
Q1 		$466K Buy
5,931
+564
+11% +$34.9K 0.35% 42
2016
Q4 		$241K Buy
+5,367
New +$263K 0.19% 50

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Opus Point Partners Management's KITE Position: Q3 2017 in Review

Opus Point Partners Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 5,915 shares — an estimated $613K sold.

Opus Point Partners Management first reported a position in KITE in Q4 2016 and held it in 3 quarters. The position peaked at $613K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Opus Point Partners Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Opus Point Partners Management sold 5,915 Kite Pharma, Inc. shares in Q3 2017, an estimated $613K.
  • Opus Point Partners Management first reported a position in Kite Pharma, Inc. in Q4 2016 and held it in 3 quarters.
  • Opus Point Partners Management's Kite Pharma, Inc. position peaked at $613K in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.